Palbociclib and Cetuximab Show Promise in Head and Neck Cancer

Many cases of head and neck squamous cell carcinoma (HNSCC) are caused by human papillomavirus (HPV); however, HNSCCs can be caused by a variety of factors, including p16INK4A inactivation (an inhibitor of cyclin-dependent kinase 4A) and overexpression of the oncogene cyclin D1. This results in the stimulation of cyclin-dependent kinase 4 and 6 (CDK4/6). Overexpression of cyclin D1 can also cause resistance to epidermal growth factor receptor (EGFR) inhibitors. To overcome this resistance, resea...
Continue reading

Palbociclib for Early Breast Cancer

A phase 2 clinical trial assessing the feasibility of adjuvant palbociclib (Ibrance®, Pfizer) and endocrine therapy for patients with early breast cancer reports that it is an effective treatment for these patients. Palbociclib, a targeted therapy drug that inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), causes the cancerous cells to stop dividing and reproducing, ultimately stopping cancer growth. This drug has already been approved for advanced metastatic breast cancer. For the study, publ...
Continue reading

Oncology Nurses’ Educational Needs: CDK4/6 Inhibitors

​Cyclin dependent kinase (CDK)4/6 inhibitors have produced tremendous advances in the treatment of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer through their targeting of hormone signals that stimulate the proliferation of cancer cells. Three CDK4/6 inhibitors have been FDA approved for the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer: palbociclib (Ibrance®, Pfizer Inc.), ribociclib (Kisqali®, Novar...
Continue reading

Metastatic Breast Cancer: Palbociclib Now Approved for Men

​The FDA has now expanded the indication for palbociclib (Ibrance®, Pfizer Inc.) in combination with an aromatase inhibitor or fulvestrant (Faslodex®, AstraZeneca) to include men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. Because breast cancer in men is rare, comprising less than 1% of all breast cancer cases, men with breast cancer are more likely to be diagnosed at an older age and with a more advanced sta...
Continue reading


Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.